drugset / Trial / NCT01457846

Efficacy and Safety of AZD4547 Versus Paclitaxel in Patients With Advanced Gastric or Gastro-oesophageal Cancer

NCT01457846

Phase 2 Terminated 960 enrolled AstraZeneca
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the efficacy, safety and tolerability of AZD4547 compared with paclitaxel in patients with advanced gastric or lower-oesophageal cancer whose tumours are found to have FGFR2 polysomy or gene amplification.

Timeline

Start
2011-11
Primary completion
2013-08
Completion
2015-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Fexagratinib Small molecule 80 mg Oral
Comparator Paclitaxel Small molecule 80 mg/m2